#1 Clinical Trials Search in Europe

Allogeneic Faecal Microbiota

This article discusses several clinical trials investigating the use of allogeneic faecal microbiota, a type of microbiome therapy, for treating various medical conditions. These trials aim to assess the safety, efficacy, and optimal dosing of faecal microbiota transplantation (FMT) in capsule or enema form for conditions such as non-alcoholic steatohepatitis, hematologic malignancies, axial spondyloarthritis, ulcerative colitis, Crohn’s disease, recurring diverticulitis, and type 2 diabetes after bariatric surgery.

Table of Contents

What is Allogeneic Fecal Microbiota?

Allogeneic fecal microbiota, also known as pooled allogeneic fecal microbiota or fecal microbiota transplantation (FMT), is an emerging treatment that uses stool samples from healthy donors to introduce beneficial gut bacteria into a patient’s digestive system[1]. The goal is to restore a healthy balance of microorganisms in the patient’s gut.

This treatment contains a diverse community of microorganisms naturally found in human stool, including bacteria, fungi, and viruses that make up the gut microbiome. By transferring this complex microbial ecosystem from healthy donors, the treatment aims to correct imbalances or deficiencies in the patient’s own gut microbiome that may be contributing to disease.

How Does It Work?

The human gut contains trillions of microorganisms that play crucial roles in digestion, immune function, and overall health. When this microbial community becomes disrupted or imbalanced, it can contribute to various health problems. Allogeneic fecal microbiota treatment works by:

  • Introducing a diverse, healthy community of gut microbes
  • Helping restore balance to the patient’s gut microbiome
  • Potentially displacing harmful microorganisms
  • Supporting proper immune function and digestion

By reestablishing a healthy gut microbiome, this treatment may help alleviate symptoms and improve outcomes for certain digestive and immune-related conditions[2].

What Conditions Can It Treat?

Allogeneic fecal microbiota is being studied as a potential treatment for several conditions related to gut health and immune function. Some of the conditions being investigated include:

  • Recurrent Clostridium difficile infection: This is currently the most well-established use for fecal microbiota transplantation.
  • Inflammatory bowel diseases: Including ulcerative colitis and Crohn’s disease[3].
  • Irritable bowel syndrome (IBS)
  • Diverticulitis: A condition where small pouches in the colon become inflamed or infected[4].
  • Metabolic disorders: Including type 2 diabetes, especially in patients who have undergone bariatric surgery[5].
  • Liver diseases: Such as non-alcoholic steatohepatitis (NASH)[1].
  • Spondyloarthritis: A type of inflammatory arthritis affecting the spine and joints[6].

It’s important to note that while some of these applications are promising, many are still in the research phase and may not be approved for routine clinical use.

How is It Administered?

Allogeneic fecal microbiota can be administered in several ways, depending on the specific product and condition being treated:

  • Oral capsules: The microbiota is encapsulated in specially designed pills that can be swallowed[2].
  • Enema: The microbiota is delivered as a liquid suspension directly into the rectum[3].
  • Colonoscopy: The microbiota is introduced into the colon during a colonoscopy procedure.

The method of administration may affect how quickly the treatment works and which parts of the digestive system it reaches. Your healthcare provider will determine the most appropriate method based on your specific condition and needs.

Safety and Side Effects

While fecal microbiota transplantation has shown promise in treating certain conditions, it’s important to be aware of potential risks and side effects. Some possible side effects include:

  • Gastrointestinal symptoms: Such as abdominal pain, bloating, diarrhea, or constipation
  • Nausea or vomiting
  • Fever
  • Fatigue

In rare cases, more serious complications can occur, such as infections. To minimize risks, donors are carefully screened, and the microbiota samples undergo rigorous testing before use[7].

Ongoing Research

Allogeneic fecal microbiota is an active area of research, with numerous clinical trials underway to better understand its potential uses, optimal dosing, and long-term effects. Some key areas of investigation include:

  • Determining the most effective dosing regimens for different conditions
  • Identifying characteristics of “good donors” whose microbiota leads to better outcomes
  • Studying the long-term effects of fecal microbiota transplantation
  • Exploring its potential in treating additional conditions beyond digestive disorders

As research progresses, our understanding of how to best use this treatment will continue to evolve. If you’re considering allogeneic fecal microbiota treatment, it’s important to discuss the latest research and potential risks and benefits with your healthcare provider.

Trial Focus Medical Condition Administration Method Key Objectives
Non-alcoholic steatohepatitis (NASH) NASH patients Oral capsules Assess efficiency, safety, and tolerability of FMT in capsule form
Hematologic malignancies Patients undergoing allogeneic hematopoietic cell transplantation Oral capsules Evaluate efficacy in preventing transplantation complications
Axial spondyloarthritis Patients with active axial spondyloarthritis Oral capsules Assess efficacy in correcting dysbiosis and clinical evolution
Ulcerative colitis Patients with active ulcerative colitis Enema Compare efficacy of FMT vs. sham transplantation on steroid-free remission
Crohn’s disease Patients with Crohn’s disease after anti-TNF withdrawal Oral capsules and enema Evaluate clinical efficacy as maintenance treatment
Recurring diverticulitis Patients with recurrent diverticulitis Oral capsules Assess efficacy in reducing frequency of acute episodes
Type 2 diabetes post-bariatric surgery Non-diabetic remission patients after bariatric surgery Oral capsules Assess efficacy on HbA1c levels and diabetes control

FAQ

  • What is allogeneic faecal microbiota? Allogeneic faecal microbiota is a type of microbiome therapy that involves transferring gut bacteria from healthy donors to patients. It aims to restore a healthy balance of gut microbes, which may help treat various medical conditions.
  • What medical conditions are being studied in these clinical trials? The clinical trials are investigating the use of allogeneic faecal microbiota for conditions such as non-alcoholic steatohepatitis, hematologic malignancies, axial spondyloarthritis, ulcerative colitis, Crohn's disease, recurring diverticulitis, and type 2 diabetes after bariatric surgery.
  • How is the faecal microbiota administered to patients? The faecal microbiota is administered in different forms depending on the trial. Some use oral capsules, while others use enemas or other methods of delivery directly to the intestines.
  • What are the main goals of these clinical trials? The main goals of these trials are to assess the safety, efficacy, and optimal dosing of faecal microbiota transplantation. They aim to determine if this therapy can improve symptoms, reduce inflammation, or lead to remission in various medical conditions.
  • Are there any potential risks or side effects associated with faecal microbiota transplantation? While the trials are designed to assess safety, potential risks may include gastrointestinal symptoms like abdominal pain, nausea, or changes in bowel habits. The trials carefully monitor for any adverse events to ensure patient safety.

Ongoing Clinical Trials on Allogeneic Faecal Microbiota

  • Study on Fecal Microbiota Transplantation to Prevent Complications in Patients After Stem Cell Transplant for Blood Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study to evaluate the effect of allogeneic faecal microbiota on the core symptoms of autism spectrum disorder in children

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study on Fecal Microbiota Transplantation and Amoxicillin-Clavulanic Acid for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Preventing Recurrent Pouchitis in Ulcerative Colitis Patients Using Fecal Microbiota Transplant and Sodium Chloride

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Allogeneic Faecal Microbiota: A type of microbiome therapy that involves transferring gut bacteria from healthy donors to patients to restore a healthy balance of gut microbes.
  • Fecal Microbiota Transplantation (FMT): A procedure in which fecal matter, or stool, is collected from a healthy donor, processed, and transferred to a recipient to treat certain medical conditions.
  • Non-alcoholic steatohepatitis (NASH): A type of fatty liver disease characterized by inflammation and liver cell damage, which can lead to fibrosis of the liver.
  • Hematologic malignancies: Cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia and lymphoma.
  • Axial spondyloarthritis: A type of inflammatory arthritis that primarily affects the spine and sacroiliac joints.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the digestive tract, primarily affecting the colon and rectum.
  • Crohn's disease: A chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract from mouth to anus.
  • Diverticulitis: Inflammation or infection of small pouches (diverticula) that can form in the walls of the colon.
  • Bariatric surgery: Weight loss surgery that involves making changes to the digestive system to help patients lose weight and improve metabolic health.
  • Type 2 diabetes: A chronic condition that affects the way the body processes blood sugar (glucose), often associated with obesity and lifestyle factors.
  • Microbiome: The collection of all microorganisms, including bacteria, viruses, and fungi, that naturally live in and on the human body.
  • Clinical trial: A research study that tests how well new medical approaches work in people, often used to evaluate the safety and efficacy of new treatments.
  • Remission: A period during a serious illness when symptoms lessen or disappear.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.

References

  1. http://clinicaltrials.eu/trial/study-on-fecal-microbiota-capsules-vs-placebo-for-treating-non-alcoholic-steatohepatitis-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-maat033-to-prevent-complications-in-patients-with-blood-cancer-undergoing-stem-cell-transplantation/
  3. http://clinicaltrials.eu/trial-id/2024-511863-27-01
  4. http://clinicaltrials.eu/trial/study-on-mbk-01-and-drug-combination-for-treating-patients-with-recurrent-diverticulitis/
  5. http://clinicaltrials.eu/trial-id/2024-511870-65-00
  6. http://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-for-patients-with-axial-spondyloarthritis-resistant-to-conventional-treatment/
  7. http://clinicaltrials.eu/trial-id/2024-511822-30-00